Psilocybin Research Starting to Identify Biomarkers with Depression

Let’s face it, the COVID-19 pandemic that rocked the world a few years back not only changed the way in which business was conducted subsequently impacting the global economy; there was also a massive change in the mental health of individuals around the world with regard to treatment and frequency of depression. Rates of depression skyrocketed and in turn so did the amount of prescription anti-depressants of which we are all familiar with the unfortunate side effects of. The age old quote of “necessity being the mother of invention” has especially come into play here when it comes to methods of improving our mental health. This was extremely auspicious timing for psilocybin treatment and research to come to the forefront of science and public thought and to become dinner conversation among people who staunchly opposed it before. Not too long ago psilocybin had a very different public perspective and through around it but now its starting to be a recognized source of improving depressive symptoms. Psilocybin treatment for depression is not new by any means, but the belief and research into its neural pathways and why it does what it does with depression and a myriad of other symptoms is. Is the public starting to become more logical with their backs against the wall due to big pharma?

It’s ironic [not] how the efficacy of methods and medications are virtually thrown away until big pharma can figure out a way to market it and make billions of dollars concocting it into their own mixture of who knows on top of the key ingredient that has been proven to be effective through research? This week’s posted article actually identifies [potentially] the specific biomarker response with regard to psilocybin therapy and depression and the why behind the mechanism. This should make not only those who suffer with depression but also practitioners and clinicians giddy with anticipation of what is coming next.

Now, maybe not a HUGE movement forward in the eye of many, potentially identifying this specific of a biomarker is a move forward in the realm of psilocybin therapy becoming not only believed and backed by those that have been through depression, but also now with the research and empiricism that can prop it up to become a legitimate treatment before big charms decided to bastardize it. 

That’s not to say just take psilocybin and you will be ok, it’s more along the lines of using a designated psilocybin dose alongside therapy. I saw a meme over the weekend about having to do the internal work (through therapy, exploration, etc.) and not just eat mushrooms which I couldn’t agree more with.